Althou gh lingual thyroid gland is the most comm on benign mass f ound at the jun ction ofthe ant erior two -thirds and the posterior one-third of the tongue, it is still a rare clinical entity. This developmental anomaly is the result of an arrested descent of the gland anlage early in the course of embryogenesis. Patients may have symptoms of dysphagia due to obstruction or even hemorrhage. These symptoms can occur at any time from inf ancy throu gh adulthood. The clini cal findin gs, laboratory tests, and radiograph ic imaging studies emplo yed in confi rming the diagn osis and in planning appropriate treatm ent hav e been evaluated. The primary therap eutic goal is to restore thyroid fun ction. We describ e a case of lingual thyroid gland and summarize the current man agement pr incipl es f or this condition.
Introduction
Lingual thyroid is the term applied to a mass of ectopic thyroid tissue located at the base of the tongue at the midline . This rare developmental anomaly is usually located between the circumvallate papillae and the epiglotti s in the area of the foramen cecum.I Lingual thyroid is believed to be the result of a failure of the embryonic gland anlage to descend from its position posterior to the tuberculum impar to its normal pretracheallocation. Thi s typically occurs between weeks 3 and 7 of embryologic development. In such cases, thyroid tissue may be depo sited in any position along this early thyroglo ssal tract. The presence of ectopic thyroid tissue has also been reported at other midline locations of the neck near the hyoid bone, the trachea, the esophagus, and even as distant as the porta hepatis.s-'
The pathogenesis of this condition remains unclear. It has been postulated that maternal antithyroid immunoglobulins may arrest the gland's descent and predi spo se the patient to poor thyroid function later in life.' Postm ortem studies have shown an incidence of 10% for lingual thyroids.' The clinic al incidence, however, varies be-From the ENT Department , Whipp s Cross Hospital, London, U.K. Reprint requests: Mr. A. Kalan, FRCS, II Arrowhead Court , James Lane, Leytonstone, London Ell INT , U.K. Phone/fax: 44-181-558-3134; e-mail: ak@kalan l. demon.co.uk 340 tween I :3,000 and I: 100,000,6the lingual thyroid being the only functioning thyroid tissue in 70 % of these cases." There is a marked preference toward fem ales; reported femal e-to-male ratio s range from 4: 1 to 7: 1. 9 • IOThe age of patients at diagnosi s ranges from 6 to 74 year s. " Clin ical evid ence of hypoth yroidi sm is found in up to 33% of pati ents. " Most lingu al thyroid gland s contain histologicall y normal tissue, although there are reports of carcinom a arising within a lingu al thyroid. "
The potential for malignant degeneration in lingual thyroid appears to be the same as for orthotopic thyroid tissue, although development of carcinoma in a lingual thyroid gland is exceptionally rare.' The incidence of thyroid disease among famil y members oflingual thyroid patients is higher than it is among the popul ation at large.':' Lingual thyroid is not associated with the parath yroid gland s because the parathyroids originate from the dorsal wing of the third and fourth pharyngeal pouches.' A 30- year-old Afro-Caribbean woman was referred to the ENT department by an anesthetist who noticed a lump at the back of her throat while he was intubating her for a cae sarean section. The intubation was problem-free. The histor y revealed that the patient had noticed some difficult y in swallowing over the previou s 12 month s, but only when she experienced a sore throat or a cold. She had never experi enced any airw ay problems, and she had no other medic al problems.
Case report
On clinical examination, the woman was noted to have a 3-by-2.5-cm midline mass on the dorsal surface of the tongue , posterior to the circumvallate papillae. The mass was smooth and pink , and it showed no evidence of hemorrhage or ulceration. The lesion was barel y visible in the rest position , but it was well visualized when the tongue was protruded forward (figure 1). There was no associated stridor or hoarseness. Examin ation of the neck revealed no palpable thyroid tissue in the normal pretracheal position. Thyroid function tests revealed normal thyroxine (T) and tri-iodothyronine (T) levels and a mildly elevated level of thyroid-stimulating hormone (TSH). Radioactive thyroid scanning showed a concentrated isotope uptake in LINGUAL THYRO ID GLA ND: CLIN ICAL EVALUATION AND CO MPREHENSIVE MANAG EMENT Figure 1 . Intraoral view of the lingual thyroid gland. This patient has a 3 x 2.5-cm midline mass on the dorsal surface of the tongue, posterior to the circumvallate papillae. The lesion was barely visible in the rest position, but it was well visualized when the tongue was protruded forward.
the area of the tongue, without any uptake in the normal thyroid position (figure 2). Axial views on computed tomography (CT) with contrast accur ately measured the gland size to be 2.5 by 2.9 em (figure 3).
A diagnosis of lingual thyroid was made . After discu s-Figu re 2. Radioactive thyroid scan shows an uptake of isotope in the base of the tongue, suggesting a long linear lingual thyroid.
Volume 78, Number 5 sion with the endocrinol ogist, the otolaryngo logist star ted the patient on suppress ive therapy with 200 ug/day of thyro xine. Repeat thyroid function testing perform ed 3 month s later showed a reducti on of TSH levels to normal, althou gh there was no apparent dec rease in the size of the thyroid. The patient has since been managed with maintenan ce doses of 100 ug/day of thyro xine and regul ar clinic al followup. Her thyroid fun ction test results have remained consi stentl y within norm al limit s.
Discussion
Lingual thyroid is the most common benign mass found at the junction of the anterior two-thirds and the posterior one-third of the tongue." Embryologically, the thyro id is derived from three primitive sources . 16 A divertic ulum in the area of the foramen cecum at the base of the tongue appears at approximately the third week of gestation and migrates down the neck to its destin ation.' ? The re it is joined during the seventh week by two lateral masses of cells derived from the fourth pharyngeal arch. These lateral anlagen, however, are inconsistently present." Defe cts in the migration of the major medi an anlage can place ectopic tissue in lingual, sublingual, prelaryngeal , and substernal sites.' ? It has also been reported in the breast and the porta hepatis regio n on rare occasions." In most cases, a total failur e of embryo logic migration produces a lingual thyroid that has no functional thyroid NA50NEX~deliversfast relieffor patients with the nasal symptoms of seasonal allergic rhinitis. This rapid onset of action was proven in two studies, in two different environments-a "park" setting and an environmental exposure unit." Maximum relief achieved within 1 to 2 weeks.
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In clinical trials, using the recommended dose, the overall incidenceof adverse events was comparable to vehicle placebo. The most commonly reported adverse events, not necessarily drug-related, were, for NA50NEX~and vehicle placebo, respectively: headache (26% vs 22%), viral infection (14% vs 11%), pharyngitis (1 2%vs 10%), epistaxis/blood-tinged mucus (1 1% vs 6%), and coughing (7% vs 6%).
WARNING: The replacement of a systemic corticosteroidwith a topical corticosteroid can be accompanied by signsof adrenal insufficiency. ' Randomized, double-blind, placebo-controlled, one-day outdoor park study ofpatients with symptoms of seasonal allergic rhinitis. One group received a single dose ofNASONEX"200I1g (n=120) orplacebo (n=119). 'Double-blind, placebo-controlled, randomized, single-dose, parallel-group comparison conducted at an environmental control unit with 279 patients treated with NASONEX"200I1g or placebo. Other adverse eventswhich occurred in less than5%butgreaterthan or equal to2%of mometasonetreated patients (regardless of relationshi p to treatment), and morefreq uentlythan intheplacebo group incl uded: arthralgia,asthma, bronchitis,chest pain, conjunctivitis, diarrhea, dyspepsia, earache, flu-l ike symptoms, myalgi a, nausea, andrhiniti s.
Rare cases of nasal ul cers and nasaland oralcandidiasis were also report edin patients treated with NASONEX Nasal Spray, 50mcg, primarilyinpatientstreatedfor longerthan4weeks.
Inpostmarketing surveillance of this product, cases of nasal burning and irritation and rarecases of nasal septal perforationhave beenreport ed.
OVERDOSAGE Therearenodataavailable ontheeffects ofacuteorchronic overdosage withNASONEX Nasal Spray, 50mcg. Becau seof low systemic bioavailability, and anabsence ofacutedrug-relatedsystemic findings in cli nical studies, overdoseis unlikely to requireanytherapyother than observation. Intranasal administration of 1600 mcg (8 times therecommendeddose of NASONEX NasalSpr ay, 50mcg) daily for29days, to healthyhuman VOlunteers, was well tolerated withnoincreased inci dence of adverse events. Si ngleintranasal doses up to 4000 mcg have been studied in humanvol unteers with no adverse effects reported. Singleoral doses up to 8000 mcg have been studied in human vol unteers with noadverse eventsreported. Chronic overdosagewith any corticosteroi d may result in signsor symptoms of hypercorticism (see PRECAUTIONS). Acuteoverdosage wi th this dosageform is unlikel y since onebottleof NASONEX Nasal Spray, 50mcg containsapproximatel y 8500 mcg of mometasone furoate. assay, and the mouse male germ-cell clastogenicity assay. Mometasone furoatealsodidnot induce unschedul ed DNAsynthesis in vivoinrat hepatocyt es.
In reproducti vetoxi citystudi esin rats, momet asonefuroateadmini steredSUbcutaneouslycaused prolonged gestation, prol ongedand difficult labor, reducedoffspr ing survival , and reduced maternal body weight gain follow ing treatment at 15 mcg/kg (approxi mately Yo themaximum reco mmended daily intranasal dose inadults ona mcg/m' basis). Impairment of fertilityin rats was not producedby subcu-taneousdosesupto15mcglkg.
Pregnancy: Teratogenic Effects: Pregnancy Category C: Mometasonefuroate caused clettpalatein miceatsubcutaneous doses of 60and180mcglkg, (approximately 2 and 4 times the maximum recommended daily intranasal dose in adults ona mcg/m' basis, respectively). Offspringsurvival wasreduced in the 180 mcglkg group. The nonteratogenic subcutaneous doselevel in micewas 20mcglkg (approximatelyli themaximum recommendeddaily intranasal doseinadultsonamcg/m' basis).
In rabbits, mometasone furoatewasteratogeni candcaused flexed frontpaws atatopi cal dermal dose of 150 mcglkg (approxi mately 14times the maximum recommended daily intranasal doseinadults ona mcg/m' basis).
In rats, mometasonefuroateproduced umbilical hernia, clett pal ate, and delayed ossification at atopical der mal dose of 600 mcglkg (approximately30times the maximum recommendeddailyintranasal dose inadultsonamcg/m' basis). At1200 mcglkg (approxi mately 60 times themaximum recommendeddail y intranasal dosein adults on a mcg/m' basis), mi crophthalmia, umbilical hernias, and delayed ossification were observedinrat pups.
Intheseterat ogenicity studies, therewerealso reductions in maternal body weight gainand effects on fetal growth (lowerfetal body weightsand/or delayed ossi fication) in mi ce (60and 180 mcglkg), rabbits (150 mcglkg), and rat s(600mcglkg).
In an oralteratology study in rabbits, at 700 mcglkg, (approxi mately70times the maximumrecommended daily intranasaldose inadultsonamcg/m' basis), increasedincidences of resorptionsand malformations, lncludlnq cleft palate and/or head malformation s (hydrocephaly or domed head) were observed. Pregnancy failure was observed in most rabbitsat 2800 mcglkg (approximately 270times the maximumrecommendeddailyintranasal doseinadul tsonamcg/m' basis).
There are no adequate, and well-controlled studies in pregnant women. NASONEX Nasal Spray, 50mcg, like othercorticosteroids, should beused during pregnancy only if the potential benefits justify the potential riskto thefetus. Experiencewith oral corticosteroids sincethei r introductionin pharmacologic,as opposed to physiologic doses suggeststhat rodents are moreproneto teratogenic eff ectsfrom cort icosteroidsthanhumans. Inaddition, becau se there isanatural increasein corticosteroidproduction during pregnancy, most women will require a lowerexo genouscort icosteroid dose and many will not need corticosteroidtreatment duringpregnancy.
NonteratogenicEffects: Hypoadrenalismmayoccur ininfantsborn towomenreceivingcorticosteroi ds duringpregnancy. Suchinf antsshouldbecarefullymoni tored.
NursingMothers: It is not knownif mometasonefuroateis excreted in human mi lk.Becauseother corticosteroidsareexcret ed in huma n milk, caution should be used when NASONEX Nasal Spray,50mcg is administeredtonursingwomen.
PediatricUse: Safetyandeffectiveness inchildrenless than 12years of age have not been established. Geriatric Use: Atotal of 203 pati ent s above 64years of age (age range64to 85)have beentreated with NASONEX Nasal Spray, 50mcg forupto3 months. Theadverse reactionsreported inthispopulation were si milar intype andinci dencetothosereport edbyyounger patients. ADVERSE REACTIONS Incontrolled US andInternational clinical sfudies, atotal of 321 0patientsreceived treatment with NASONEX NasalSpray, 50mcg atdoses of 50to 800 mcg/day. Themajority of patients (n = 2103) were treated wi th 200 mcg/day. Atotal of350 patientshave beentreatedfor 1year or longer. Theoverall incidence ofadverse events forpatients treated withNASONEX Nasal Spray, 50mcg was comparable topatients treated wi th thevehicle placebo. Also, adverse events did not differsignificantlybased onage, sex, orrace.
Thr ee percent ofpatients in clinical trials discontinued treatmentbecauseof adverse events;thi s rate was similarforthevehicleandactive comparators.
All adverse eventsreportedby 5% or more of patients (regardless of relationshipto treatment) who received NASONEX Nasal Spray, 50mcg200 mcg/day in cl inicaltrials, andthatweremorecommon with NASONEX Nasal Spray, 50mcgthanpl acebo,aredisplayedinthetablebelow.
ADVERSE EVENTSFROMCONTROLLED CLINICAL TRIALS INSEASONAL ALLERGIC AND PERENNIAL ALLERGIC RHINITIS (PERCENTOF PATIENTS REPORTING)
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'calculatedontheanhydrousbasis BRIEFSUMMARY (For fullPrescribingInformation,see package insert.) INDICATIONSAND USAGE NASONEX Nasal Spray, 50mcg is indicated for the prophylaxis and treatment of thenasal symptoms of seasonal allergic rhinitis and thetreatment of thenasal symptoms of perennial allergicrhinitis, in adul ts and chil dren 12years of age and older. In patients witha known seasonal allergenthatprecipitates nasalsymptoms of seasonal allergic rhinitis,initiation ofprophylaxis wi th NASONEXNasalSpr ay, 50mcgis recommended2 to 4 weeks prior to theanticipated start of the poll enseason. CONTRAINDICATIONS Hypersensitivity to anyof the ingredients of this preparati oncontraindicates itsuse. WARNINGS Therepl acement ofa systemic corticosteroid wi thatopical corticosteroid can beaccompanied by signsof adrenal insufficiencyand, in addition, some patient s may experi ence symptoms of withdrawal ; ie,joint and/or muscul ar pai'l, lassitude, and depression. Careful attention must be given when patients previously treated for prolonged periods with systemic corticosteroidsare transferred to topical cort icosteroids, with careful monitoringfor acute adrenal insufficiencyin response to stress. This is particularly important inthosepat ients whohaveassociat edasthma orother clinical condi tions where toorapi d a decrease in systemic corticosteroid dosing ma y cause asevereexacerbationof their symptoms.
If recommended doses of intranasaicorticosteroidsareexceeded or if individualsarepanicularly sensitiveor predi sposed by virtue of recent systemic steroi d therapy,symptoms ofhypercorticism mayoccur, including very rarecases of menstrual irreg ularities, acneiform lesions, and cushingoi d features. If such changes occur, topical corticosteroidsshould bediscontinuedslowly, consistentwithaccepted procedures fordiscontinuingoral steroidtherapy.
Persons who are on drugs whichsuppress the immune system are more susceptibleto infections than healthyindividual s. Chickenpox andmeasles, for example,can havea moreseriousor even fatal coursein nonimmune chil dren or adultsoncorticosteroids. Insuchchildren oradultswho havenothad thesedi seases, particular careshould betaken toavoid exposure. Howthedose,route,and durati onof cort icosteroid administration affects therisk of devel oping a disseminated infection is notknown. The contribution of the underlyingdiseaseand/or prior corticosteroid treatmentto therisk is alsonot known. If exposed to chickenpox, prophylaxis with varicella zoster immune globin (VZIG) may be indicated. If exposedto measles, prophylaxis with pooledintramuscul arimmunoglobulin (IG) may be indicated. (See therespective package inserts for complete VZIG and IGprescribinginformation.) If chickenpoxdevel ops, treatmentwithantiviral agentsmay beconsidered. PRECAUTIONS General: Inclini calstudies with NASONEXNasal Spr ay,50mcg, the devel opment of localized infectionsof thenose and pharynx wit h Candidaalbicans has occurredonl y rarely.Whensuch aninfectiondevelops, useof NASONEX Nasal Spray, 50mcg shoul d bediscontinuedandappropriate local orsystemictherapyinstituted, if needed.
Nasal corticosteroi dsshouldbeusedwi thcaution, if at all,in patients wi thactive orquiescenttuberculousinfection ofthe respiratorytract, or in untreated fungal, bacterial, systemic viralinfections, or ocular herpessi mplex.
Rarely, immediate hypersensitivi ty reactions may occuratter the intranasal administration of mornetasone furoatemonohydrat e. Extremerareinstances of Wheezinghave beenreported.
Rareinstances ofnasal septum perforationand increased intraocularpressure havealso been reported followingthe intranasal application of aerosolized cortcosterolds. Aswi th anylong-termtopi cal treatmentofthenasal cavity, patients using NASONEX Nasal Spray, 50mcg over severalmonthsor longer shouldbeexaminedperiodically forpossiblechangesinthenasal mucosa.
Because of the inhibitoryeffect of corti costeroids onwound healing, patients who have experienced recent nasal septumulcers, nasal surgery, ornasaltrauma shoul d not useanasal corticosteroid unti l healinghasoccurred.
Glaucoma and cataract formationwas evaluated inonecontrolledstudy of12 weeks'duration and one uncontrolled studyof 12 months' durationin pat ients treated with NASONEXNasalSpray, 50mcgat .200 mcg/day, usingintraocular pressure measur ements and slit lamp exami nation.Nosignificant change from baseline was not edin the mean intraocular pressure measurements forthe 141 NASONEX-t reated patients in the12-week study, ascompared wi th 141 pl acebo-treatedpatients. Noindivi dual NASONEXtreated patient was noted to havedeveloped asignificant elevation in intraocularpressure or cataractsin thi s 12-week study. Likewise, nosignificantchange from baselinewasnot ed inthe meanintraocularpressuremeasurements forthe139 NASONEX-treated patients inthe12-monthstudyand again,nocataracts weredetected inthese patients. Nonetheless,nasal andinhaled corticosteroidshavebeenassociated with the devel opment of glaucoma and/or cataracts. Therefore, close follow-upis warranted in patients with a changeinvisionandwithahi storyofglaucoma and/orcata racts.
When nasal corticosteroidsareused at excessi vedoses, systemic corticoste roideffects such as hypercorticism andadrenal suppressio n may appear. If such changes occur, NASONEX Nasal Spray, 50 mcg shoul d bedisconti nuedslowl y, consistentwith accepted procedures for discontinuing oral steroidtherapy.
InformationforPatients: Patients beingtreated wit h NASONEXNasalSpray, 50mcg should be given thefoll owing Informationand instructions. Thisinformation isintendedtoaid inthesafeand eff ectiveuse of this medication. It is notadisclosure ofall intended or possibleadverseeffects. Patients should use NASONEX Nasal Spr ay, 50mcg atregularintervals (oncedail y) since its effectiveness depends onregular use. Improvementinnasal symptomsofallergicrhinitis has beenshownto occur wi thin11hoursatter thefirstdose based ononesi ngle-dose, parallel-group studyofpatients inanoutdoor "park" setting (park study)and one environmentalexposureunit (EEU) study andwithin 2 days atterthe firstdoseintwo randomized, double-bl ind, pl acebo-controlled, parall el-group seasonal allergic rhinitisstudies. Maximumbenefi t is usually achieved withi n 1 to 2 weeks atter initiationof dosing. Patients shoul d takethemedication asdirectedand should notincr ease theprescribeddosage byusing it morethanonceaday inanattempt toincrease itseffectiveness. Patientsshoul d contact their physicianif symptoms do not improve, or if the condition worsens. To assureproperuse of this nasal spray, and to attain maximum benefit, patients should read andfollowtheaccompanying Patient'sInstructions for Usecarefully.
PatientsshouldbecautionednottosprayNASONEX Nasal Spray, 50mcginto the eyes. Persons who are on immunosuppressant doses of corti costeroids should be warned to avoid exposureto chickenpox or measles, and patients should also beadvised thatif they areexposed, medical adviceshouldbe sought without delay.
Carcinogenesis, Mutagenesi s, ImpairmentofFertility: In Sprague Dawley rats, mometasone furoate demonstrat edno statisticallysignificant increase in the incidence of tumors at an inhalation doseof 67mcglkg (approximat el y 3 timesthe maximum recommended dail y intranasal dose in adults ona mcg/m' basis). In Swiss CD-l mice, mometasone furoate demonstratednostatistically significant increase intheinci denceoftumorsat aninhalationdoseof 160mcglkg (approximately 4 times themaximum recommended dail yintranasaldose inadults onamcg/m' basis).
At cyt otoxic doses, mometasone furoateproduced anincrease in chromosomeaberrations in vitro in Chinesehamster ovary-cellcultures inthenonactivationphase, butnot inthepresenceof rat liver S9fraction. Mometasone furoate was not mut agenic in themouse-lymphom aassay andtheSa/monel/alE. Figure 4 . The initial evaluation of lingual thyroid is based on those symptoms that bring it to the attention of the otolaryngolog ist.
Management protocol for the patient with lingual thyroid
tissue in the nor mal pretracheal position. Cys tic ch anges within lingual thyroid tissue have been reported."
In 1869, Hickman first reported a case oflingual thyroid that res ulte d in neona tal suffocation." A paper by Goddard in 1760 may well have described an earl ier case." Symptomatic cases are rare; on ly abo ut 400 suc h cases have been reported in the literature." Th e estima ted prevalence of visible lesions is about I:10,000,6.24altho ugh thyroid tissue is present in 10%of male and female tongue s dissected at postm ort em. v"
Evaluation. The initial ev aluation of lingu al thyroid is based on tho se symptoms that brin g it to the attention of the otolar yngo log ist ( figure 4 ). Th ese sy mptom s include dy sph agia (with or witho ut decreased oral intake), dysp hon ia, dyspn ea, and hemorrhage.!' Stridor may also be present at any time , but it is mos t . com mon in neo nates. " Ling ual thyroid is thought to have two primary clinical pictures, which are based on the patient' s age and onse t of symptoms." On e gro up of patient s consists of infa nts and yo ung children whose lingual thyroid is detected on routine screening. Th ese patient s ofte n suffe r from failur e to thri ve and ment al retardation. Th e second gro up of pati ent s present s followin g the on set of dy sphagia and oropharyngea l obstruction before or during puberty . Glandul ar hypertrophy occ urs in respon se to the rise in TSH levels that is generated by the increase in metabolic demand for th yroid horm on e d uring puberry." A similar effect is see n in other states of metabolic stress, such as pregn ancy, traum a, infection, and menopause ."
Clinical examination. The initial eval uatio n invo lves a thorough head and neck exami nation. Atte ntion is paid to visua lizing the orophary nx, becau se a lingu al thyroid gland typi call y appea rs as a raised mass posterior to the circumva llate pap illae. Th e col or of the ma ss varie s from light pink to bright red or KALAN, TARIO neck is performed to check for the presence of thyroid tissue in the normal pretr acheal position . Laboratory tests. The primary laboratory studies are thyroid function tests. The se tests often demon strate normal-to-m arginal gland function, norm al-to-lo w levels of T 3 and T 4 , and high levels of TSH and thyro globulin ." Hyperth yroidism, although rare, has been recorded."
Imaging studi es. Radiologic imaging studies are indispensable in the evaluation of ectopic thyroid . Technetium scanning should be performed to confirm the clinical diagnosis. These scans typically show radionuclide activity at the level of the mouth and no apparent activity in the normal position of the neck. This method avoids the need for a diagnostic biopsy, which carries the risks of intractable hemorrhage and acute thyrotoxicosis.24 CT provide s an accurate method of determining the gland size and, because the thyroid naturally accumulates iodide, it can often be performed without contr ast."
Magnetic resonance imaging (MRI) is a new way of assessing gland size and position." On MRI, the signal intensity of the normal thyroid tissue is higher than that of muscular tissue on both Tl-and T2-wei ghted images. The location of the mass at the base of the tongue and its sharp delineation help MRI establish the correct diagnosis. Calcifications and cystic changes are best depicted on T2weighted images; they are seen as low-and high-signal regions , respectivel y. The ability to study the lingual thyroid in the sagittal plane allows for a better evaluation of the extent of the lesion and the extent of oro-and hypopharyngeal invol vement. MRI' s multiplanar capability and its high degree of soft-tis sue resolution results in a better delineation of the lesion, and makes MRI a method of choice to study lingual thyroids in a noninva sive way.
Ultrasound examinations oflingual thyroid glands have been found to be less dependable. P-" Depending on the skill of the sonographer, ultrasound may ormay not reveal I • details about the consi stency of the gland and any possible nodules or cysts contained within it. Thi s type of inform ation would aid in identifying and following an enlarging compon ent of a lingu al gland without the need for additional ionizing radiation. Selective external carotid angiography can detect aberrant pattern s of vascularization ." For example, the superior thyroid arteries are often absent, and the lingual thyroid recei ves its blood supply from the lingual and facial arteries. Williams et al argued that the surgeon must know the exact vascular anatomy when con sidering therapeutic emboli zation or surgery.31Embolization or ligature ofthe supply ing arteries is though t to be the safest method of therapy, followed by either surgic al operation (for which a precise knowledge of the vascular supply is mandatory) or the administration of radioactive iodine (for patients who refu se the option of surgery )."
Treatment. Because of the paucity of data, there is no 346 real consensus in the literature about the proper management of lingual thyroid . The goals of any comprehensive line of management should be to relieve the obstruct ive symptoms produced by the protrudin g mass without endangering the life of the patient or producing mutil ating scars. If possible, lifelong hypothyroid ism should be prevented, particul arly in child ren and women of childbearing age. Suppressive therapy. The best initial guide to treatment is the presence or absenc e of symptoms." Suppressive therapy with exogenous thyroid hormone is the mainst ay of medical management. The goal of therapy is to suppress TSH levels and thereby remove the stimulus for gland enlargement. This approach is mandatory for patients with mild sympt oms and for asymptomatic patient s who have elevated TSH levels.
Suppression also seems to be warranted for asymptomatic euthyroid patients in order to prevent the hypothyroid state that eventu ally develops in most patients and which leads to glandular hypertrophy. Clini cal exams can then be performed and thyroid function monitored at regular intervals, ideally every 3 months or less. Adhering to such a regimen help s control gland size and the resultant mild symptoms in most patients; however, the rate of reduction in the size of the ectopic gland is very slow, so dramatic results should not be expected." Patient s who remain euthyroid without evidence of gland enl argem ent can be checked at 3-month intervals throughout the first year of suppressiv e therapy. More frequent visits should be scheduled during periods of metabolic stress, such as puberty or pregnancy.
Radiotherapy. The ectopic thyroid tissue can also be ablated by a therapeu tic dose of 131 1, after which the patient should be placed on thyroid hormone replacement for life.I I However, radioiodine results in unpredictable thyroid shrinkage, and it should be reser ved for patients who refuse or who are unfit for surgery . Radioactive iodine is particul arly contraindic ated in women of childbearing age."
Excision. Surgery is necessary for selected patients who become symptomatic or whose initial symptoms worsen while on suppress ive therapy. In fact, surgery becomes crucial under conditions such as severe or repeated hemorrh age, gland enlargement with dysphagia and significant airway comp romise, and dysphoni a. When surgery is contempl ated, CT and MRI are helpful in determining the best approa ch for total gland excision. It seems that even in the best of hands, total excision of an ectopic thyroid is difficult , regardless of the surgical approach. At best, thyroid remn ants will be left at the base of the tongue, and they might hypertrophy again unless they are checked by repl acement therapy or functional transplanted thyroid tissue." Whether or not tran splanted thyroid tissue will produ ce enough horm ones to meet the phy siologic need s of the patient is difficult to predict, but when it does, it eliminates the nec essity for lifelong thyroid hormone replacement ther apy.
Preoperative tracheostomy and nasotracheal intubation are both effective in sec uring an airw ay during surgery. The deci sion to use one method in favor of the other is based on the surg eon's preference and the availability of an intensive care un it to manage a sedated and intubated pat ient until postoperative edema resolves.
Surgical excision of the lingu al thy roid ca n be performed transorally or through the neck with a midline or lateral pharyngotomy. Irrespective of the surgical technique , an intentional partial excision that leave s thyroid tissue at the base of the tongue should be avoided, because . the tissue may hypertrophy again, which cau ses myxedema in most cas es. 18 Remnants of thyroid tissue following an attempted total excision are usually located deep in the tongu e subs tance and may be les s likel y to produce obstructive sym ptoms should they hypertrophy again. Most cases reported in literature have involved tran soral exci sion .'? Access can be gained by incising the full thickness of the cheek, by incising the length of the tongue in the line of the median fibrous septum, and even by splitting the mandible in the midline." Th e majo r problem with the oral approach, beside s poo r exposure, is inadequate control of bleeding, which can be life-threatening. Kamat et al described a series of bilateral ligations oflingual arteries at the level of the cornu of the hyoid bone through separate skin incisions before completely splitting the tongue in the midline. " Thi s procedure has been associated , in some cases, with a devastating necro sis of the tongu e.
Atiyeh et al argued that their modification of the standard techn iqu e of splitting the ton gue , in which the surgeon slices only the posterior two-thirds of the tongue in the midline down to the hyoid bone, offers many advantages ." Opening the tongue like a book ex poses the dor sal lingual arteries at the base of the tongu e. The bleeding that invariably follows can be eas ily controlled under direct vision with the application of suture ligature s. Atiyeh' s procedure exposes the anterior and posterior aspects of the lingu al thyroid to direct visu al inspection , and it wid ens the surgical field. Ati yeh et al maintain that the ir modification , unlike pharyngotomy and the transhyoid approach, minimizes the risk of injury to vital structures (maj or blo od vessels, the nose, and the neck ) because dis section is restricted to the midline within the tongue muscle substance. Direct communicati on between the neck skin and the oropharyn x, which carr ies the risk offistul a form at ion (albe it rarely), is completel y avoided, which make s thi s approach highly attractive, part icularl y for youn g women.
Pha ryngotomy. Lateral pharyngotomy has been described by some to be the most satisfactory approach in term s of exposure and case dissection. " However, this 348 view is not shared by others." A skin creas e inci sion is made at the level of the superior border of the thyroid cartilage , extending from the midline to the posterior border of the sternomastoid. The sternomastoid muscle is retracted laterally, and dissection continues medial to the carotid sheath to expose the pharynx and larynx. The mu scles attached to the superior border of the hyoid are divided at the lateral end with cutting diathermy. The underlying muco sa is di vided with scis sor s to enter the pha rynx through the vallecula. The excision is then extend ed inferiorly, immediately posterior to the superior cornu of the thyroid cartilage. Part of the hyoid may be dissected to improve access to a large lesion. Although the ectopic thyroid is a benign lesion, there may be deep infiltration, so an adequate margin is essential to avoid recurrence. Preoperative CT will help indicate how wide the excision margin should be. A V-shaped wedge of ton gue should be excised to allow primary clo sure of the defect. The pha ryngeal mucosa and mu sculature are then sutured and the skin clo sed in normal fashion.
Steinwald et al desc rib ed the retention of portions of lin gual thyroid as vascularized flaps rotated down toward the neck. " This can be achieved by a transverse superhard skin incision with an H-sh aped tongue open ing . There is, however, no evidence that the ret ained thyroid tissue in this technique is sufficient to avoid myxedema or that the technique is superior to autotransplantation of thyroid tissue ." Extensive dissection and surgical manipul ation in the oropharyngeal region produce severe postoperative edema, which makes tracheo stomy mand atory in certain cases. Postoperatively, the patient may develop hypothyroidism, so replacement thyroxine is oft en required.
Autotransplantation of the thyro id tissue is an alternative for euthyroid patients; the tissue is moved by free graft into the anterior rectu s sheath or under the strap muscles' :" or by tran spo sition into a submandibular site. Repl acement thyroxine is not administered during the immediate postoperative period, to prevent suppression of the graft; 30% of patients who unde rgo transplant ation remain euthyroid without replacement thyro xine ."
Postoperative hypocalcemia has been reported in a patient with an abnormally loc ated parathyroid gland, which was in clo se prox imity to a lingual thyroid." However, Sauk' and Steinwald et aP9share the view that there is little or no risk of postoperative hypocalcemia, because the parathyroid glands , which ari se from third and fou rth branchial arches, follow a different path of embryonic descent and are still found in their normal positions in the neck . 
